Neurology

The Pharmacy Times® Neurology resource center provides clinical news and articles, information about upcoming conferences and meetings, updated clinical trial listings, and other resources.

What can we help you find?
[[thumbnail_alt_text]]
The symptoms of depression in caregivers of patients with dementia exacerbates over time. 
 
[[thumbnail_alt_text]]
COVID-19 has been found in the brain post-mortem. 
 
[[thumbnail_alt_text]]
Without coordinated care to ensure proper adherence, the resulting costs can become downright staggering for health systems.
[[thumbnail_alt_text]]
Although cytokine storms are usually associated with severe COVID-19, study indicates less severe disease may also be at risk of cytokine storm.
 
[[thumbnail_alt_text]]
Delirium is a common syndrome experienced by patients with COVID-19 while being treated in the ICU, according to a session at the 2020 ASHP Midyear Clinical Meeting and Exhibition.

 
[[thumbnail_alt_text]]
The Pharmacy Times® Pharmacy Focus podcast provides the latest industry news and information, thought-leader insights, clinical updates, patient counseling tools, and innovative solutions for the everyday practice and business of pharmacy. 
[[thumbnail_alt_text]]
The tau protein can help identify Alzheimer disease before cognitive decline begins. 

 
[[thumbnail_alt_text]]
This week on Pharmacy Times, there are a number of important topics that will be covered and posted throughout the week
[[thumbnail_alt_text]]
The treatment of mental illness has long been a quandary for medical professionals throughout history. But historically, mental illness has been more loosely defined than it is today.
[[thumbnail_alt_text]]
Compared with patients with focal epilepsy, those with genialized epilepsy have a higher risk of obstructive sleep apnea. 
 
[[thumbnail_alt_text]]
A final vote that assessed whether the findings from the EMERGE trial served as primary evidence for the efficacy of aducanumab in Alzheimer disease was 10–0 that the trial did not provide evidence.
[[thumbnail_alt_text]]
The current acute treatments for migraines have shown efficacy and safety, however, approximately one-third of people do not respond, cannot use these options due to contraindications, or report dissatisfaction in therapy.